456 related articles for article (PubMed ID: 30661763)
41. BRCA carriers, prophylactic salpingo-oophorectomy and menopause: clinical management considerations and recommendations.
Finch A; Evans G; Narod SA
Womens Health (Lond); 2012 Sep; 8(5):543-55. PubMed ID: 22934728
[TBL] [Abstract][Full Text] [Related]
42. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
Doren A; Vecchiola A; Aguirre B; Villaseca P
Climacteric; 2018 Dec; 21(6):529-535. PubMed ID: 30295091
[TBL] [Abstract][Full Text] [Related]
43. Quality of life after risk-reducing salpingo-oophorectomy in women with a pathogenic BRCA variant.
Zilski N; Speiser D; Bartley J; Roehle R; Blohmer JU; Keilholz U; Goerling U
J Sex Med; 2023 Dec; 21(1):33-39. PubMed ID: 37973412
[TBL] [Abstract][Full Text] [Related]
44. A Psychological Perspective on Factors Predicting Prophylactic Salpingo-Oophorectomy in a Sample of Italian Women from the General Population. Results from a Hypothetical Study in the Context of BRCA Mutations.
Gavaruzzi T; Tasso A; Franiuk M; Varesco L; Lotto L
J Genet Couns; 2017 Oct; 26(5):1144-1152. PubMed ID: 28337671
[TBL] [Abstract][Full Text] [Related]
45. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA
Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751
[TBL] [Abstract][Full Text] [Related]
46. Breast Cancer Risk and Breast-Cancer-Specific Mortality following Risk-Reducing Salpingo-Oophorectomy in
Gaba F; Blyuss O; Tan A; Munblit D; Oxley S; Khan K; Legood R; Manchanda R
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900415
[TBL] [Abstract][Full Text] [Related]
47. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation.
Finch A; Metcalfe KA; Chiang JK; Elit L; McLaughlin J; Springate C; Demsky R; Murphy J; Rosen B; Narod SA
Gynecol Oncol; 2011 Apr; 121(1):163-8. PubMed ID: 21216453
[TBL] [Abstract][Full Text] [Related]
48. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy.
Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
Gynecol Endocrinol; 2010 Aug; 26(8):568-77. PubMed ID: 20632911
[TBL] [Abstract][Full Text] [Related]
49. Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.
Huber D; Seitz S; Kast K; Emons G; Ortmann O
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2035-2045. PubMed ID: 33885953
[TBL] [Abstract][Full Text] [Related]
50. Changes in Bone Density in Carriers of BRCA1 and BRCA2 Pathogenic Variants After Salpingo-Oophorectomy.
Chan LN; Chen LM; Goldman M; Mak JS; Bauer DC; Boscardin J; Schembri M; Bae-Jump V; Friedman S; Jacoby VL
Obstet Gynecol; 2023 Jul; 142(1):160-169. PubMed ID: 37290104
[TBL] [Abstract][Full Text] [Related]
51. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
52. The psychosexual effects of risk-reducing bilateral salpingo-oophorectomy in female BRCA1/2 mutation carriers: A systematic review of qualitative studies.
Hickey I; Jha S; Wyld L
Gynecol Oncol; 2021 Mar; 160(3):763-770. PubMed ID: 33317909
[TBL] [Abstract][Full Text] [Related]
53. Bone mineral density and fractures after risk-reducing salpingo-oophorectomy in women at increased risk for breast and ovarian cancer.
Fakkert IE; Abma EM; Westrik IG; Lefrandt JD; Wolffenbuttel BH; Oosterwijk JC; Slart RH; van der Veer E; de Bock GH; Mourits MJ
Eur J Cancer; 2015 Feb; 51(3):400-8. PubMed ID: 25532426
[TBL] [Abstract][Full Text] [Related]
54. [Hormone replacement therapy after salpingo-oophorectomy in BRCA 1/2 mutation carriers does not increase the risk of breast cancer].
Breda AS; Blaakær J
Ugeskr Laeger; 2014 Sep; 176(38):. PubMed ID: 25294198
[TBL] [Abstract][Full Text] [Related]
55. Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.
Manchanda R; Gaba F; Talaulikar V; Pundir J; Gessler S; Davies M; Menon U;
BJOG; 2022 Jan; 129(1):e16-e34. PubMed ID: 34672090
[TBL] [Abstract][Full Text] [Related]
56. Endometrial Cancer in Germline BRCA Mutation Carriers: A Systematic Review and Meta-analysis.
Matanes E; Volodarsky-Perel A; Eisenberg N; Rottenstreich M; Yasmeen A; Mitric C; Lau S; Salvador S; Gotlieb WH; Kogan L
J Minim Invasive Gynecol; 2021 May; 28(5):947-956. PubMed ID: 33249269
[TBL] [Abstract][Full Text] [Related]
57. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Guidozzi F
Climacteric; 2016 Oct; 19(5):419-22. PubMed ID: 27426853
[TBL] [Abstract][Full Text] [Related]
58. Use of systemic hormone therapy in BRCA mutation carriers.
Domchek S; Kaunitz AM
Menopause; 2016 Sep; 23(9):1026-7. PubMed ID: 27504919
[TBL] [Abstract][Full Text] [Related]
59. Breast MRI fibroglandular volume and parenchymal enhancement in BRCA1 and BRCA2 mutation carriers before and immediately after risk-reducing salpingo-oophorectomy.
DeLeo MJ; Domchek SM; Kontos D; Conant E; Chen J; Weinstein S
AJR Am J Roentgenol; 2015 Mar; 204(3):669-73. PubMed ID: 25714301
[TBL] [Abstract][Full Text] [Related]
60. Hormone replacement therapy after menopause and risk of breast cancer in BRCA1 mutation carriers: a case-control study.
Kotsopoulos J; Huzarski T; Gronwald J; Moller P; Lynch HT; Neuhausen SL; Senter L; Demsky R; Foulkes WD; Eng C; Karlan B; Tung N; Singer CF; Sun P; Lubinski J; Narod SA
Breast Cancer Res Treat; 2016 Jan; 155(2):365-73. PubMed ID: 26780555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
